<DOC>
	<DOCNO>NCT01620489</DOCNO>
	<brief_summary>This trial conduct Europe United States America ( USA ) . The aim trial investigate efficacy safety liraglutide subject type 2 diabetes moderate renal impairment . The trial medication add-on subject 's stable pre-trial OAD and/or insulin regimen .</brief_summary>
	<brief_title>Efficacy Safety Liraglutide Versus Placebo add-on Existing Diabetes Medication Subjects With Type 2 Diabetes Moderate Renal Impairment</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Subjects diagnose type 2 diabetes stable diabetes treatment ( unchanged medication unchanged dose ) 90 day prior screen visit include : Monotherapy duocombinations metformin and/or SUs and/or pioglitazone . Metformin use caution subject moderate renal failure must use accordance local metformin label guideline . Or Monotherapy combination metformin and/or pioglitazone and/or basal premix insulin . Insulin adjustment ( total daily dose ) equal 10 % within 90 day prior screen visit confirm investigator acceptable . Metformin use caution subject moderate renal failure must use accordance local metformin label guideline . Combination pioglitazone insulin use caution accord local labelling guideline HbA1c 710 % ( inclusive ) Moderate renal impairment diagnose 90 day prior screen visit confirm eGFR ( glomerular filtration rate ) 3059 mL/min/1.73 m2 per MDRD ( modification diet renal disease ) formula screen visit Body Mass Index ( BMI ) 2045 kg/m^2 ( inclusive ) Recurrent severe hypoglycaemia hypoglycaemic unawareness judge investigator Treatment antidiabetic medication ( ) state inclusion criterion period 90 day prior screen . Previous shortterm ( equal 7 day total ) treatment rapidor shortacting insulin connection intercurrent illness allow discretion investigator Impaired liver function , define ALAT ( alanine aminotransferase ) equal 2.5 time upper normal limit History chronic pancreatitis idiopathic acute pancreatitis Within past 180 day follow : Episode unstable angina , acute coronary event , cerebral stroke/transient ischemic attack ( TIA ) significant cardiovascular event ( include e.g . arrhythmias conduction delay ECG ( electrocardiogram ) ) Heart failure define New York Heart Association ( NYHA ) class IV A systolic blood pressure equal 180 mmHg diastolic blood pressure equal 100 mmHg Rapidly progress renal disease ( e.g. , acute glomerulonephritis ) discretion investigator Use immunosuppressive treatment within 90 day prior screen Diagnosis treatment cancer previous 5 year ( except basal cell skin cancer squamous cell skin cancer ) Proliferative retinopathy maculopathy require acute treatment judge investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>